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In a prospective trial, the diagnostic performance of the second version of the
troponin T rapid assay (Trop T; cutoff 0.2 mg/L) was compared with the
quantitative cardiac-speci® c troponin T assay (cTnT ELISA; cutoff 0.1 mg/L)
and other established cardiac markers such as CK, CK-MB activity, CK-MB
mass and myoglobin. Additionally, a 30-day follow-up was performed to
determine the suitability of the Trop T assay and the reference markers for
short-term risk strati® cation. Two-hundred-and-eighty-six consecutive patients
with chest pain and suspected acute myocardial infarction (AMI) were enrolled
in two CCU departments. Serial blood specimens were taken at admission and at
3, 6, 12, 24, 48, 72 and 96 h after admission. According to the biochemical
criterion CK-MB mass, the patients were classi® ed as having AMI in 154
patients (54%), unstable angina (UAP) in 72 patients (27%) and no evidence for
acute cardiac ischemia in 55 patients (19%). Analytical method comparison of
Trop T with cTnT ELISA (cutoff 0.1 mg/L) showed a good agreement, Trop T
yielded only 4% false-negative and 3% false-positive results. The diagnostic
performance of Trop T for the detection of AMI was only slightly inferior
compared to cTnT ELISA. Beyond 12 h after admission, Trop T and cTnT
ELISA maintained a sensitivity close to 100%, whereas the sensitivity of the
other cardiac markers decreased sharply. The diagnostic sensitivity of Trop T for
the detection of minor myocardial damage in UAP patients was the same as for
cTnT ELISA. Death within 30 days’ follow-up occurred only in AMI patients
with a positive Trop T test result within the ® rst 6 h after admission. The
admission Trop T and cTnT ELISA were the only signi® cant biochemical
predictors of major cardiac events. In conclusion, these data show that Trop T
has similar diagnostic sensitivity as cTnT ELISA and is a useful tool to con® rm
acute or subacute myocardial infarction. Trop T is an excellent marker in
detecting minor myocardial damage in UAP patients and is suitable for short-
term risk strati® cation.
Scand J Clin Lab Invest 2000; 60: 665 ± 676
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Acute coronary syndromes represent a spectrum
in the severity of coronary artery disease from
suspected unstable angina through acute myo-
cardial infarction. In patients with these syn-
dromes, the presence and amount of myocardial
damage can be assessed from myocardial
proteins appearing in the circulation. The
recent availability of cardiac-speci® c troponin
T (cTnT) and troponin I (cTnI) [1 ± 5] presents
an opportunity to improve clinical assessment
over other cardiac markers such as routine
serial CK testing [6, 7], creatine kinase-MB
(CK-MB) [9 ± 10] and myoglobin [11 ± 15]. It is
now well established that elevation of cTnT and
cTnI in patients with acute coronary syndromes
is an indicator of myocardial damage and
identi® es patients at increased risk for subse-
quent myocardial injury or death, irrespective
of CK or CK-MB levels [16 ± 20]. Cardiac
troponin T or troponin I rises in blood to
proportionally higher levels than cardiac
enzymes like CK and CK-MB. Cardiac tropo-
nin stays elevated for a week or more and can
be differentiated from its skeletal muscle iso-
form by immunological techniques. These
developments have not only allowed the detec-
tion of myocardial infarction, but also of
minimal myocardial damage in patients with
unstable angina, thus far undetectable by other
diagnostic methods. Earlier studies have shown
that these patients are at higher risk for
subsequent cardiac events [16 ± 18, 21 ± 25].
Quantitative cTnT ELISA testing by labora-
tory systems needs sample preparation and
mostly sample transportation away from the
point of care. To overcome these limitations an
assay for rapid bedside detection of cTnT
elevations has been developed and has become
available for clinical use [26 ± 30]. This qualita-
tive (positive or negative) cardiac troponin T
rapid assay (Trop T) makes a result available
within 20 min. I.e. the time to positive Trop T
result decreases, with increasing cTnT concen-
tration. The clinical use of such test strip
depends upon its diagnostic performance and
practicability, compared with the quantitative
cTnT testing performed in the central clinical
chemistry laboratory. The aims of the present
study were ® rst to assess and compare the time
dependent diagnostic performance of Trop T
with that of the quantitative cTnT ELISA and
other cardiac markers CK, CK-MB mass and
myoglobin including a suggested combined
measurement of cTnT ELISA and myoglobin.
Especially, we investigated the agreement
between the Trop T and cTnT ELISA and
the learning curve effect of Trop T. Second, to
determine whether Trop T was a useful tool at
or nearby the CCU, i.e. at the point of care, and
in the hands of multiple readers and to prove
whether Trop T is suitable to predict subse-
quent cardiac events.
MATERIALS AND METHODS
Patients
Two-hundred-and-eighty-six consecutive
patients with chest pain and suspected acute
myocardial infarction were admitted to two
coronary care units (Heidelberg, Germany, and
Rotterdam, The Netherlands) were included.
The study period was from June 1995 to May
1996. None had suffered a documented acute
myocardial infarction (AMI) within the pre-
vious week. Patients admitted more than once
during the study period were included only on
their ® rst admission. Eight serial blood samples
were drawn: at admission and at 3, 6, 12, 24, 48,
72 and 96 h after admission.
Analytical methods
1. Cardiac troponin T was measured qualita-
tively using a whole blood rapid bedside test
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(Trop T version 2, Roche Diagnostics, Man-
nheim, Germany) [28, 29]. The nominal detec-
tion limit of the assay was 0.2 mg/L; results were
read visually after precisely 20 min. All Trop T
readings were done without delay, i.e. very
shortly after blood sampling. In Rotterdam
readings were performed during 12 months in
two phases by laboratory technicians (n~20) of
the Thorax laboratory, located nearby the
CCU. Two phases can be distinguished: part
of the Trop T data were gathered after an initial
familiarisation; the other part was collected
after an extra training period and under strictly
standardized reading conditions. In Heidelberg
the strip readings were performed within 3
months by two physicians at the CCU.
2. Quantitative Troponin T analysis was
performed using an enzyme-linked immunosor-
bent assay (cTnT ELISA; cardiospeci® c Enzy-
mun Troponin T version 2, Roche Diagnostics)
[31] on an ES 600 automated analyser with
streptavidin-coated tubes (Roche Diagnostics)
The cutoff value for detection of AMI was
0.1 mg/L.
3. Creatine kinase and creatine kinase MB
activities were measured at 30³C by means of a
N-acetylcysteine-activated optimised ultraviolet
test (Merck; Darmstadt, Germany). Creatine
kinase MB activity was determined by immu-
noinhibition. The upper limits of the reference
intervals of creatine kinase and creatine kinase
MB activity are 110 IU/L and 14 IU/L respec-
tively.
4. Creatine kinase MB mass concentration was
measured by a microparticle enzyme immuno-
assay (Abbott Laboratories; Abbott Park,
Illinois) using an automated analyser (Abbott
IMx). We used 5 mg/L as an upper limit of the
reference interval.
5. Myoglobin was determined by a commer-
cially available immunoturbidimetric assay
(Merck; Darmstadt, Germany). The upper
limits of the reference interval are 64 mg/L for
women and 76 mg/L for men.
Clinical classi® cation
Two cardiologists examined independently
the admission ECG for the initial diagnosis of
acute myocardial infarction. If the results were
discordant assessment by a third cardiologist
was asked for. The cardiologists and the
attending physicians were blinded for the
Trop T and cTnT ELISA readings. The ® nal
diagnosis of AMI was based on the WHO
criteria [32] using a time-dependent increase of
CK-MB mass above 5 mg/L as the biochemical
criterion and ST segment elevation of at least
2 mm in 2 precordial leads or at least 1 mm in
two extremity leads in the ECG. Thus, by
de® nition, the sensitivity for AMI detection of
CK-MB mass 5 mg/L was 100%. The group of
patients with unstable angina (episodes of chest
pain with ECG changes, but without elevated
CK MB mass45 mg/L) was further subdivided
into patients with or without minimal myocar-
dial damage (MMD) and by an increased cTnT
ELISA 0.1 mg/L [33].
Clinical data
Clinical data were recorded including pre-
vious cardiac history, classi® cation of chest pain
at hospital admission, admission clinical events,
inhospital clinical course and medication at
discharge. During a follow-up of 30 days
cardiac events such as (recurrent) myocardial
infarction, documented by ECG changes and
CK-MB mass elevations, cardiac death and
noncardiac death or the need for a coronary
angioplasty procedure (PTCA) or coronary
artery bypass graft surgery (CABG) were
registered in the hospital records and, if
needed, by contacting the referral hospitals or
the attending general practitioners.
Statistical methods
The diagnostic sensitivities for the detection
of AMI were calculated non-cumulative from
standard statistical formulas [34]. The boolean
combination of cTnT ELISA and myoglobin
result was regarded as positive if cTnT or
myoglobin was positive, and negative if both
cTnT and myoglobin were negative. Differences
between sensitivity and speci® city of the differ-
ent markers at different times after onset of
symptoms were calculated with the chi-squared
test for differences in proportions. Relative risks
(RR) with accompanying 95% con® dence inter-
vals (95% CI) were used to investigate whether
the cardiac markers were predictive of mortality
or MI. A con® dence interval not including 1.0
was considered to be signi® cant. Statistical
comparisons associated with P values less
than 0.05 were considered to be signi® cant.
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RESULTS
Patient demographics
The study collective comprised of 286 con-
secutive patients with chest pain and suspected
myocardial infarction admitted to the CCU
departments of Heidelberg and Rotterdam.
There were no signi® cant differences in baseline
characteristics between the two centers. The
mean age was 62 years (range 31 ± 92 years) and
75% were male. The median time interval
between onset of symptoms and admission
was 3.5 h (0 ± 23 h). The diagnosis of acute
myocardial infarction (AMI) was con® rmed in
154 patients (AMI prevalence 54%). Seventy-
seven patients (27% of all) suffered from
unstable angina (UAP). Thirteen patients
(17% of the UAP patients; 5% of all) had
elevated troponin T values, while maximum
CK-MB mass values in the series remained
55 mg/L, and were thus classi® ed as having
minor myocardial damage (MMD). Fifty-® ve
patients were classi® ed as having no evidence
for acute cardiac ischemia. Table I gives the
baseline characteristics.
Method comparison of Trop T with cTnT
ELISA
Fig. 1 shows the distribution of the analytic
performance of Trop T as a function of the
quantitative cTnT ELISA concentration in each
of the corresponding blood samples. The x-axis
shows the cTnT ELISA concentrations at class
intervals of 0.10 mg/L in the range 0.00 ±
2.00 mg/L. All samples with cTnT 2.00 mg/l
are accumulated in the last test class. Positive
results of Trop T rapid assay are shown in the
upper ® eld, negative ones in the lower ® elds.
The numbers at the top or bottom of each
column indicate the number of positive or
negative results within each test class interval.
The ascending curve shows the increasing
percentage of positive Trop T results with
increasing cTnT ELISA values: from 5% at
cTnT 0.10 mg/L to 33% in the interval 0.10 ±
0.19 mg/L, 67% in the interval 0.20 ± 0.29 mg/L,
increasing to 100% in case of cTnT
values40.60 mg/L. The area of interest com-
prises the zone around the possible detection
limit. Within this overlap zone of negative and
positive results, 0.10 ± 0.29 mg/L Trop T showed
28/53 (53%) positives, within 0.30 ± 0.39 mg/L it
showed 44/68 (65%) positive results. The 50%
intersect for Trop T thus occurs just below
cTnT 0.30 mg/L.
Diagnostic performance
The time course of the diagnostic sensitivity
and speci® city for the detection of AMI are
illustrated in Fig. 2 for Trop T, cTnT ELISA,
myoglobin and for a combination of myoglobin
and cTnT ELISA in relation to the time after
admission. At admission myoglobin had highest
sensitivity. Up to 4 to 8 h after onset of
symptoms the sensitivity of Trop T was slightly
lower than that of cTnT ELISA (80% vs. 92%;
p~0.02). From 12 h onwards the sensitivities of
Trop T and cTnT ELISA remained close to
TABLE I. Baseline demographics and clinical course.
Diagnosis at discharge
Total
(n~286)
AMI
*
(n~154) 54%
UAP{
(n~77) 27%
Other
(n~55) 19%
Age (year)s 62 62 64 63
Male (%) 74 73 79 69
Time from onset of symptoms
until admission (median hours) 3.5 3.5 3.75 3.5
History %
Prior myocardial infarction 41 45 35 20
Prior CABG{ 12 10 16 11
Prior PTCA
§
22 18 35 15
Risk factors %
Hypercholesterolaemia 28 29 29 24
Diabetes 21 22 21 16
*AMI~acute myocardial infarct ion; {UAP~unstable angina pectoris; {CABG~Coronary artery bypass graft;
§PTCA~Percutaneous transluminal coronary angioplasty.
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100%, whereas the sensitivities of CK-MB mass
and myoglobin decreased sharply. Myoglobin
and CK-MB mass were initially most sensitive
up to 8 h.
The speci® cities of Trop T and cTnT ELISA
for detecting non-AMI remained similar during
the whole time from onset of symptoms up to
96 h (85% to 95%) and were apparently less
speci® c than CK and CK-MB mass (95% to
100%) (data not shown). The boolean combina-
tion of cTnT ELISA and myoglobin (positive if
cTnT or myoglobin positive; negative if both
are negative) resulted in an improved early
sensitivity, albeit, at the cost of lower speci® city
(below 80%). Already at admission the sensi-
tivity was 71% and increased within 3 h to 97%.
In the AMI patient group at least one of CK-
MB mass values was by de® nition positive
( 5 mg/ml) in 100% of the patients, followed by
cTnT ELISA (96%) and Trop T (88%).
Of the 77 UAP patients 17% had an elevated
cTnT ELISA and 14% a positive Trop T. CK-
MB was by de® nition not elevated in these
patients.
Learning curve
In Rotterdam readings were performed
during 12 months by 20 clinical laboratory
technicians in two phases, i.e., before starting
the clinical study an extensive familarization
program was run; midway, extra training was
given especially for improving the faint marker
line at the detection limit and strictly standar-
dization reading conditions were introduced.
In Heidelberg two physicians performed the
readings within 3 months. It turned out that the
Trop T needed a learning phase (Fig. 3). The
study period was evenly divided in quartiles.
The extra training in Rotterdam had a sub-
stantial in¯ uence on the analytical sensitivity
(increase from 93% to 98%). Analytical speci-
® city of the physicians decreased in the second
half of the study from 99% to 91%.
Clinical events (30-days follow-up)
Table II gives the cardiac events within 30
days after admission according to the diagnosis
at discharge (AMI, UAP or another diagnosis).
Within 30 days, only patients with AMI and an
early positive Trop T test (0 to 6 h after
admission) died. As far as reinfarction and
coronary intervention is concerned no signi® -
cant differences depending on the Trop T result
were found in the AMI group. In the UAP
group, none of 66 patients with persistently
negative Trop T results suffered from myocar-
dial (re)infarction and 2 patients out of 11
patients (18%) with at least one positive Trop T
test developed a (re)infarction.
Seven of the 13 UAP patients with MMD
FIG. 1. Frequency distributions of Trop T-positive (upper ® eld) and negative results (lower ® eld) related to
cTnT ELISA concentrations (abscissa) in 1766 samples.
Diagnostic performance of the bedside troponin T test 669
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(54%) underwent a coronary intervention
(CABG or PTCA), whereas 20 out of 64
non-MMD patients (31%) underwent a coron-
ary intervention. In the `` other’’ patient group
no major cardiac events were found.
All admission cardiac markers were univari-
ate predictors of death or non-fatal myocardial
infarction through day 30 (Table III). The
combined endpoint of death, non-fatal infarc-
tion, CABG or PTCA occurred in 50% of the
patients with a positive Trop T at admission
compared to 32% of the patients with a negative
test. The admission Trop T and cTnT ELISA
were the only signi® cant predictors of any
major cardiac event.
DISCUSSION
The present study evaluated the diagnostic
performance of Trop T in patients with acute
coronary syndromes, as compared to quantita-
tive cTnT ELISA and other established cardiac
markers by extensive serial testing from admis-
sion up to 96 h. While quantitative troponin T
testing with laboratory systems needs sample
transportation and sample preparation, the
qualitative rapid assay Trop T, tested in this
study, allows bedside determination of troponin
T only within 20 min after blood sampling. This
study showed that Trop T has a comparable
sensitivity for AMI and speci® city for non-AMI
to cTnT ELISA. Within 6 h after admission the
sensitivity of Trop T was only slightly lower
than that of cTnT ELISA, due to the twofold
higher detection limit (0.2 mg/L vs. 0.1 mg/L)
and false-negative readings. It turned out that
training experience was important with this
second version of Trop T. The learning curve
FIG. 2. The time course of the diagnostic sensitiv-
ities and speci® cities for the detection of acute myo-
cardial infarction for Trop T, cTnT ELISA,
myoglobin, CK, CK-MB activity, CK-MB mass,
and a combination of myoglobin and cTnT ELISA
in relation to the time after admission. - - TROP T,
- - cTnT, - - CK-MB mass, - - Myoglobin, - -
Positive: cTnT or myoglobin positive. Negative:
cTnT and myoglobin negative.
FIG. 3. Learning curve of the analytical sensitivity
and speci® city of Trop T throughout the study
period. The study period was evenly divided in
quartiles. - -Analytical sensitivity. Analytical
speci® city.
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(Fig. 3) does illustrate that nicely. Visual
detection of a positive Trop T at the cutoff
limit was especially prone to interobserver
variability around the detection limit. Besides
the eye sensitivity and the experience of the
observer, the type of light (sunlight, arti® cial
light), the incidence of the light (direct, indirect)
and the eventual use of a reading lamp
de® nitely affected Trop T readings. Therefore,
extra training was given midway in Rotterdam.
In parallel, test strip reading conditions were
standardized by introducing a reading lamp and
by instructing the technicians to carefully
inspect test strips with faint marker lines at
20 min under different corners of light inci-
dence. In the fourth quartile of the study
period, more positive Trop T results were
found, both correct and incorrect. Conse-
quently, the analytical sensitivity increased
whereas the analytical speci® city decreased
almost by a similar percentage. In Heidelberg,
no extra training was given. The two physicians
who did the readings reached almost 100%
sensitivity in the second quartile of the study
period. Surprisingly, both analytical sensitivity
and speci® city declined to about 90% in the last
quarter. The authors speculate that after an
initial period of attentive visual inspection,
some habituation appeared, leading to an
increased number of false-positives and false-
nagatives. In summary, the very faint marker
line of the second generation Trop T test strips
in case of troponin T concentrations around the
cutoff limit clearly hampered correct reading
and surely explains a great deal of the
discrepant readings.
At the time of the study only one antibody
existed. We may speculate that some of the
discrepancies between Trop T and cTnT ELISA
resulted from cross reactivity of the one
unspeci® c antibody with skeletal troponin T.
However, in our opinion, this did not con-
tributed essentially to the relative high number
of the `` false-positives’’ . At present, this pro-
blem has been solved by the existence of more
antibodies.
This investigation has used the second
version of Trop T. After this study was ® nished
(in 1996) a third generation of Trop T has been
developed [35]. The latest version of both visual
and electronically read Trop T have the same
cutoff (0.1 mg/L) as the quantitative cTnT
ELISA. Notwithstanding, the authors are con-T
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vinced that this study has still merit as visually
read Trop T is still widely used in current
clinical practice.
The early sensitivity of Trop T was similar to
CK-MB mass, which had such a high sensitivity
because it was used as classi® cation criteria for
AMI. Beyond 6 hours and up to 96 hours after
admission the sensitivities of Trop T and cTnT
ELISA remained close to 100%, whereas the
CK-MB mass decreased sharply.
To rule out AMI on the basis of cardiac
markers, some time is needed for the marker
released from necrotic cells to reach the
circulating blood and to rise above the upper
reference limit of the assay used, as well as for
the pre-analytical, the analytical and reporting
phases in the speci® c hospital setting [36 ± 38].
The use of new cardiac markers may increase
sensitivity, which may result in a more frequent
diagnosis of myocardial damage. However, it is
still controversial whether serial testing
improves the prediction of hospital mortality
[39, 40]. In this study AMI patients with an
early (up to 6 h after admission) positive result
for Trop T had a signi® cantly higher risk of
death than patients with a late positive or
persistently negative result.
Furthermore troponin T detects minor myo-
cardial damage in patients after an episode of
acute myocardial ischemia even when the WHO
criteria for an acute myocardial infarction are
not ful® lled [22 ± 26]. The latter is the reason for
the relatively poor speci® city for the former
diagnosis based on `` AMI’ ’ of Trop T or cTnT
ELISA compared to CK-MB mass. However,
several studies provided ® rm evidence that these
patients with MMD were at high risk for
cardiac events [24, 41 ± 43]. This study also
showed that the diagnostic sensitivity of the
Trop T rapid test for the detection of high-risk
UAP patients with MMD was nearly the same
as for cTnT ELISA. In UAP patients with a
positive Trop T test the percentage of cardiac
events was higher than in the Trop T negative
group.
The study diagnostic sensitivities for Trop T,
cTnT ELISA and conventional cardiac markers
for detection of massive acute and subacute
myocardial infarction and minimal myocardial
damage change rapidly in the early hours after
onset of symptoms, as reported earlier [36]. In
this study the highest ef® cacy to detect AMI
was obtained with the use of a combination of
the cTnT ELISA and myoglobin, apparently at
the expense of a lower speci® city. Myoglobin
alone had a relatively high sensitivity in the ® rst
3 to 6 h, albeit its speci® city was low. The same
results were seen in several other studies [44 ±
50]. After 6 h both troponin T and CK-MB
mass had the highest diagnostic sensitivity in
the AMI group. The latter markers appear not
to be suitable as early markers for ruling out
AMI. Trop T had similar diagnostic sensitivity
as cTnT ELISA. The measurement of troponin
T is especially important at 6 ± 24 h from
symptom onset. At this time, a positive result
will identify all patients with acute myocardial
infarction and also patients with unstable
angina, who have sustained minor myocardial
damage. We agree with a recent proposal which
recommended a strategy which included utilisa-
tion of two biochemical markers for routine
AMI diagnosis [51, 52]: an early, unspeci® c
marker such as myoglobin (reliably increased in
blood within 6 h after onset of symptoms) and
a late, cardiospeci® c marker such as troponin T
(relative late appearance in blood but with high
sensitivity and speci® city for myocardial injury
and remaining abnormal for many days after
onset).
TABLE III. Admission cardiac markers as predictors of mortality, myocardial infarction, CABG and PTCA
within 30 days after admission.
Death Death/MI
Death/MI
CABG/PTCA
RR* 95% CI{ RR 95% CI RR 95% CI
Trop T 10.4 2.3 ± 48.0 2.9 1.3 ± 6.8 1.5 1.1 ± 2.1
cTnT ELISA 9.3 1.2 ± 71.0 7.6 1.8 ± 32.1 1.7 1.2 ± 2.4
Myoglobin 4.2 1.0 ± 17.3 2.7 1.0 ± 7.1 1.3 0.8 ± 2.3
CK-MB mass 13.2 4.3 ± 41.2 4.9 1.9 ± 12.7 1.3 0.8 ± 2.3
*RR~relative risk; {95%CI~95% con dence interval. For the other abbreviations, see Table I.
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CONCLUSION
These data show that Trop T has similar
diagnostic sensitivity as cTnT ELISA and is a
useful tool to con® rm acute or subacute
myocardial infarction. It can be performed
conveniently in a ®` eld’ situation, such as in
the hands of minimally trained physicians, as
well as clinical chemistry laboratory technicians.
The rapid Trop T assay at the point-of-care
allows a qualitative determination from whole
blood with a turn-around-time of only 20 min.
The diagnostic performance of the Trop T test
strip is nearly similar to that of the quantitative
cTnT ELISA and is superior compared to CK-
MB mass and the cardiac enzymes in unstable
angina patients with minimal myocardial
damage.
ACKNOWLEDGEMENTS
We thank the reviewers for their extensive
comments and suggestions. This study was
funded by Roche Diagnostics GmbH. Trop T
and cTnT ELISA are trademarks of a member
of the Roche group.
REFERENCES
1 Katus HA, Remppis A, Looser S, Hallermeier K,
Scheffold T, KuÈ bler W. Enzyme linked immuno
assay cardiac troponin T for the detection of acute
myocardial infarction in patients. J Mol Cell
Cardiol 1989; 21: 1349 ± 53.
2 Katus HA, Remppis A, Neumann FJ, Scheffold T,
Diederich KW, Vinar G, Noe A, Matern G,
Kuebler W. Diagnostic ef® ciency of troponin T
measurements in acute myocardial infarction.
Circulation 1991; 83: 902 ± 12.
3 Mair J, Artner-Dworzak E, Lechleitner P, Smidt J,
Wagner I, Dienstl F, Puschendorf B. Cardiac
troponin T in diagnosis acute myocardial infarc-
tion. Clin Chem 1991; 37: 845 ± 52.
4 Mair J, Dienstl F, Puschendorf B. Cardiac
troponin T in the diagnosis myocardial injury.
Crit Rev Cl Lab Sci 1992; 29: 31 ± 57.
5 Antman EM, Tanasijevic MJ, Thompson B,
Schactman M, McCabe CH, Cannon CP,
Fischer GA, Fung AY, Thompson C, Wybenga
D, Braunwald E. Cardiac ± speci® c troponin I
levels to predict the risk of mortality in patients
with acute coronary syndromes. N Engl J Med
1996; 31; 335: 1342 ± 9.
6 Apple FS, Lowe M. Cardiac troponin subunits I
and T versus creatine kinase ± MB in the diagnosis
of myocardial injury and acute myocardial infarc-
tion. In: Check sample. Chicago, III: American
Society of Clinical Pathologists, Clinical Chemis-
try no. CC ± 95 ± 7 (CC ± 265), 1995; 35: 99 ± 116.
7 Keffer JH. Myocardial markers injury. Evolution
and insights. Am J Clin Pathol 1996; 105: 305 ± 20.
8 Puleo PR, Guadagno PA, Roberts R, Perryman
MB. Sensitive, rapid assay of subforms of crea-
tine kinase MB in plasma. Clin Chem 1989; 35:
1452 ± 5.
9 Puleo PR, Guadagno PA, Roberts R, Scheel MV,
Marian AJ, Churchill D, Perryman MB. Early
diagnosis of acute myocardial infarction based on
assay for subforms creatine kinase-MB. Circula-
tion 1990; 82: 759 ± 64.
10 Puleo PR, Meyer D, Wathen C, Tawa CB,
Wheeler S, Hamburg RJ, Ali N, Obermueller
SD, Triana JF, Zimmerman JL. Use of a rapid
assay subforms creatine kinase-MB to diagnose or
rule out acute myocardial infarction. N Engl J
Med 1994; 331: 561 ± 6.
11 Gibler WB, Gibler CD, Weinshenker E,
Abbottsmith C, Hedges JR, Barsan WG,
Sperling M, Chen IW, Embry S, Kereiakes D.
Myoglobin as an early indicator of acute myo-
cardial infarction. Ann Emerg Med 1987; 16:
851 ± 6.
12 Brogan GX Jr, Friedman S, McCuskey C, Cooling
DS, Berrutti L, Thode HC Jr, Bock JL. Evalua-
tion of a new rapid quantitative immunoassay for
serum myoglobin versus CK ± MB for ruling out
acute myocardial infarction in the Emerg depart-
ment. Ann Emerg Med 1994; 24: 665 ± 71.
13 Tucker JF, Collins RA, Anderson AJ, Hess M,
Farley IM, Hagemann DA. Value serial myoglo-
bin levels in the early diagnosis of patients
admitted for acute myocardial infarction. Ann
Emerg Med 1994; 24: 704 ± 8.
14 Montague C, Kircher T. Myoglobin in the early
evaluation of acute chest pain. Am J Clin Pathol
1995; 104: 472 ± 6.
15 Woo J, Lacbawan FL, Sunheimer R, LeFever D,
McCabe JB. Is myoglobin useful in the diagnosis
acute myocardial infarction in the emergency
department setting? Am J Clin Pathol 1995; 103:
725 ± 9.
16 Ohman EM, Armstrong PW, Christenson RH,
Granger CB, Katus HA, Hamm CW, O’Hanesian
MA, Wagner GS, Kleiman NS, Harrell FE Jr,
Califf RM, Topol EJ. Cardiac troponin T levels
for risk strati® cation in acute myocardial ischemia.
GUSTO IIA Investigators. N Engl J Med 1996;
335: 1333 ± 41.
17 Lindahl B, Venge P, Wallentin L. Relation
between troponin T and the risk subsequent
cardiac events in unstable coronary artery disease.
The FRISC study group. Circulation 1996; 93:
1651 ± 7.
18 Antman EM, Tanasijevic MJ, Thompson B,
Schactman M, McCabe CH, Cannon CP,
Fischer GA, Fung AY, Thompson C, Wybenga
D, Braunwald E. Cardiac ± speci® c troponin I
levels to predict the risk of mortality in patients
Diagnostic performance of the bedside troponin T test 673
Sc
an
d 
J C
lin
 L
ab
 In
ve
st 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Sw
et
s I
nf
or
m
at
io
n 
Se
rv
ic
es
 
Fo
r p
er
so
na
l u
se
 o
nl
y.
with acute coronary syndromes. N Engl J Med
1996; 335: 1342 ± 9.
19 Hamm CW, Goldmann BU, Heeschen C,
Kreymann G, Berger J, Meinertz T. Emerg
room triage of patients with acute chest pain by
means of rapid testing for cardiac troponin T or
troponin I. N Engl J Med 1997; 337: 1648 ± 53.
20 Olatidoye AG, Wu AH, Feng YJ, Waters D.
Prognostic role of troponin T versus troponin I in
unstable angina pectoris for cardiac events with
meta ± analysis comparing published studies. Am J
Cardiol 1998; 81: 1405 ± 10.
21 Collinson PO, Stubbs PJ. The prognostic value of
serum troponin T in unstable angina. N Engl J
Med 1992; 327: 1760 ± 1.
22 Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P,
Peheim E, Ljungdahl L, Goldmann B, Katus HA.
The prognostic value of serum troponin T in
unstable angina. N Engl J Med 1992; 327: 146 ± 50.
23 Ravkilde J, Horder M, Gerhardt W, Ljungdahl L,
Pettersson T, Tryding N, Moller BH, Hamfelt A,
Graven T, Asberg A. Diagnostic performance and
prognostic value of serum troponin T in suspected
acute myocardial infarction. Scand J Clin Lab Inv
1993; 53: 677 ± 85.
24 Burlina A, Zaninotto M, Secchiero S, Rubin D,
Accorsi F. Troponin T as a marker of ischemic
myocardial injury. Clin Biochem 1994; 27: 113 ±
21.
25 Wu AH, Valdes R Jr, Apple FS, Gornet T, Stone
MA, May® eld ± Stokes S, Ingersoll ± Stroubos
AM, Wiler B. Cardiac troponin ± T immunoassay
for diagnosis of acute myocardial infarction. Clin
Chem 1994; 40: 900 ± 7.
26 Antman EM, Grudzien C, Sacks DB. Evaluation
of a rapid bedside assay for detection of serum
cardiac troponin T. JAMA 1995; 273: 1279 ± 82.
27 Mach F, Lovis C, Chevrolet JC, Urban P, Unger
PF, Bouillie M, Gaspoz JM. Rapid bedside whole
blood cardiospeci® c troponin T immunoassay for
the diagnosis of acute myocardial infarction. Am J
Cardiol 1995; 75: 842 ± 5.
28 DeFilippi CR, Parmar RJ, Potter MA, Tocchi M.
Diagnostic accuracy, angiographic correlates and
long ± term risk strati® cation with the troponin T
ultra sensitive rapid assay in chest pain patients at
low risk for acute myocardial infarction. Eur
Heart J 1998; 19 Suppl N: N42 ± 7.
29 MuÈ ller ± Bardorff M, Freitag H, Scheffold T,
Remppis A, Kubler W, Katus HA. Development
and characterization of a rapid assay for bedside
determinations of cardiac troponin T. Circulation
1995; 92: 2869 ± 75.
30 Gerhardt W, Ljungdahl L, Collinson PO, Lovis C,
Mach F, Sylven C, Rasmanis G, Leinberger R,
Zerback R, Muller ± Bardorff M, Katus HA. An
improved rapid troponin T test with a decreased
detection limit: a multicentre study of the
analytical and clinical performance in suspected
myocardial damage. Scand J Clin Lab Invest 1997;
57: 549 ± 57.
31 MuÈ ller ± Bardorff M, Hallermayer K, Schroder A,
Ebert C, Borgya A, Gerhardt W, Remppis A,
Zehelein J, Katus HA. Improved troponin T
ELISA speci® c for cardiac troponin T isoform:
assay development and analytical and clinical
validation. Clin Chem 1997; 43: 458 ± 66.
32 Bernard R, Corday E, Eliasch H, et al. Nomen-
clature and criteria for diagnosis of ischemic heart
disease. Report of the Joint International Society
and Federation of Cardiology/World Health
Organization Task Force of Standardization of
Clinical Nomenclature. Circulation 1979; 59: 607 ±
609.
33 Gerhardt W, Ljungdahl L. Rational diagnostic
strategy in diagnosis of ischemic myocardial
injury. S ± troponin T and S ± CK MB (mass)
time series using individual baseline values. Scand
J Clin Lab Invest 1993; 53 (Suppl 215): 47 ± 59.
34 Galen RS, Gambino SR. Beyond normality. The
predictive value and ef® ciency of medical diag-
noses. New York: Wiley, 1975.
35 Muller ± Bardorff M, Rauscher T, Kampmann M,
Schoolmann S, Laufenberg F, Mangold D,
Zerback R, Remppis A, Katus HA. Quantitative
bedside assay for cardiac troponin T: a comple-
mentary method to centralized laboratory testing.
Clin Chem 1999; 45: 1002 ± 8.
36 De Winter RJ, Koster RW, Sturk A, Sanders GT.
Value of myoglobin, troponin T, and CK ±
MBmass in ruling out an acute myocardial
infarction in the emergency room. Circulation
1995; 92: 3401 ± 7.
37 Kost GJ, Kirk JD, Omand K. A strategy for the
use of cardiac injury markers (troponin I and T,
creatine kinase ± MB mass and isoforms, and
myoglobin) in the diagnosis of acute myocardial
infarction. Arch Pathol Lab Med 1998; 122: 245 ±
51. Review.
38 Cobbaert C, Hermens WT, Kint PP, Klootwijk
PJ, Van de Werf F, Simoons ML. Thrombolysis ±
induced coronary reperfusion causes acute and
massive interstitial elease of cardiac muscle cell
proteins. Cardiovasc Res 1997; 33: 147 ± 55.
39 Wu AH, Feng YJ, Contois JH, Azar R, Waters D.
Prognostic value of cardiac troponin I in patients
with chest pain. Clin Chem 1996; 42: 651 ± 2.
40 Kollef MH, Ladenson JH, Eisenberg PR. Clini-
cally recognized cardiac dysfunction: an indepen-
dent determinant of mortality among critically ill
patients. Is there a role for serial measurement of
cardiac troponin I? Chest 1997; 111: 1340 ± 7.
41 Stubbs P, Collinson P, Moseley D, Greenwood T,
Noble M. Prognostic signi® cance of admission
troponin T concentrations in patients with myo-
cardial infarction. Circulation 1996; 94: 1291 ± 7.
42 Lindahl B, Venge P, Wallentin L. Relation
between troponin T and the risk of subsequent
cardiac events in unstable coronary artery disease.
The FRISC study group Circulation 1996; 93:
1651 ± 7.
43 Simoons ML, van den Brand M, Lincoff M,
Harrington R, van der Wieken R, Vahanian A,
Rutsch W, Kootstra J, Boersma E, Califf RM,
Topol E. Minimal myocardial damage during
coronary intervention is asscociated with impaired
outcome. Eur Heart J 1999; 20: 1112 ± 9.
44 Ohman EM, Casey C, Bengtson JR, Pryor D,
674 R. T. van Domburg et al.
Sc
an
d 
J C
lin
 L
ab
 In
ve
st 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Sw
et
s I
nf
or
m
at
io
n 
Se
rv
ic
es
 
Fo
r p
er
so
na
l u
se
 o
nl
y.
Tormey W, Horgan JH. Early detection of acute
myocardial infarction: additional diagnostic infor-
mation from serum concentrations myoglobin in
patients without ST elevation. Brit Heart J 1990;
63: 335 ± 8.
45 Mair J, Artner ± Dworzak E, Lechleitner P,
Morass B, Smidt J, Wagner I, Dienstl F,
Puschendorf B. Early diagnosis of acute myocar-
dial infarction by a newly developed rapid
immunoturbidimetric assay for myoglobin. Brit
Heart J 1992; 68: 462 ± 8.
46 Roxin LE, Cullhed I, Groth T, Hallgren T, Venge
P. The value serum of myoglobin determinations
in the early diagnosis of acute myocardial infarc-
tion. Acta Med Scand 1984; 215: 417 ± 25.
47 Grenadier E, Keidar S, Kahana L, Alpan G,
Marmur A, Palant A. The roles of serum
myoglobin, total CPK, and CK ± MB isoenzyme
in the acute phase myocardial infarction. Am
Heart J 1983; 105: 408 ± 16.
48 Castaldo AM, Ercolini P, Forino F, Basevi A,
Vrenna L, Castaldo P, et al. Plasma myoglobin in
the early diagnosis of acute myocardial infarction.
Eur J Clin Chem Clin Biochem 1994; 32: 349 ± 53.
49 Montague C, Kircher T. Myoglobin in the early
evaluation of acute chest pain. Am J Clin Pathol
1995; 104: 472 ± 662.
50 Kilpatrick WS, Wosornu D, McGuinness JB, Glen
AC. Early diagnosis of acute myocardial infarc-
tion: CK ± MB and myoglobin compared. Ann
Clin Biochem 1993; 30: 435 ± 8.
51 Plebani M, et al. Diagnostic strategies in myo-
cardial infarction using myoglobin measurement.
Eur Heart J 1998; 19 Suppl N: N12 ± 5.
52 Gibler B, Apple FH, Valdes R, Warshaw M, Wu
AHB. Recommendations for markers in triage of
patients with chest pain. Clin Chem 1998; 44
Suppl: S62.
Received: 7 March 2000
Accepted: 14 August 2000
Diagnostic performance of the bedside troponin T test 675
Sc
an
d 
J C
lin
 L
ab
 In
ve
st 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Sw
et
s I
nf
or
m
at
io
n 
Se
rv
ic
es
 
Fo
r p
er
so
na
l u
se
 o
nl
y.
